Cogent Biosciences, Inc.
0 products tracked · names used in filings: Cogent Biosciences, Inc.
Upcoming milestones
bezuclastinib: PDUFA target action date (Gastrointestinal Stromal Tumors (GIST))
Cogent Biosciences, Inc. (COGT); bezuclastinib; status: set; "Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026 NonAdvSM PDUFA target action date December 30, 2026; AdvSM PDUFA target action date June 29, 2027 Cash balance of $791.1 million…"; filed 2026-11-05 · source
Recent milestones
No recent milestones.
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.